Reversible lysine-targeted probes reveal residence time-based kinase selectivity

被引:52
作者
Yang, Tangpo [1 ]
Cuesta, Adolfo [1 ]
Wan, Xiaobo [1 ,2 ]
Craven, Gregory B. [1 ]
Hirakawa, Brad [3 ]
Khamphavong, Penney [3 ]
May, Jeffrey R. [3 ]
Kath, John C. [3 ]
Lapek, John D. [3 ]
Niessen, Sherry [3 ]
Burlingame, Alma L. [2 ]
Carelli, Jordan D. [3 ]
Taunton, Jack [1 ]
机构
[1] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA USA
[3] Pfizer Global Res & Dev La Jolla, San Diego, CA USA
关键词
N-MYC; INHIBITOR; AURORA; DISCOVERY; HYDROLYSIS; REFINEMENT; MUTATIONS; KINETICS; AZD9291;
D O I
10.1038/s41589-022-01019-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The expansion of the target landscape of covalent inhibitors requires the engagement of nucleophiles beyond cysteine. Although the conserved catalytic lysine in protein kinases is an attractive candidate for a covalent approach, selectivity remains an obvious challenge. Moreover, few covalent inhibitors have been shown to engage the kinase catalytic lysine in animals. We hypothesized that reversible, lysine-targeted inhibitors could provide sustained kinase engagement in vivo, with selectivity driven in part by differences in residence time. By strategically linking benzaldehydes to a promiscuous kinase binding scaffold, we developed chemoproteomic probes that reversibly and covalently engage >200 protein kinases in cells and mice. Probe-kinase residence time was dramatically enhanced by a hydroxyl group ortho to the aldehyde. Remarkably, only a few kinases, including Aurora A, showed sustained, quasi-irreversible occupancy in vivo, the structural basis for which was revealed by X-ray crystallography. We anticipate broad application of salicylaldehyde-based probes to proteins that lack a druggable cysteine.
引用
收藏
页码:934 / +
页数:16
相关论文
共 49 条
  • [1] Towards automated crystallographic structure refinement with phenix.refine
    Afonine, Pavel V.
    Grosse-Kunstleve, Ralf W.
    Echols, Nathaniel
    Headd, Jeffrey J.
    Moriarty, Nigel W.
    Mustyakimov, Marat
    Terwilliger, Thomas C.
    Urzhumtsev, Alexandre
    Zwart, Peter H.
    Adams, Paul D.
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2012, 68 : 352 - 367
  • [2] The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth (vol 35, pg 1902, 2016)
    Bago, Ruzica
    Sommer, Eeva
    Castel, Pau
    Crafter, Claire
    Bailey, Fiona P.
    Shpiro, Natalia
    Baselga, Jose
    Cross, Darren
    Eyers, Patrick A.
    Alessi, Dario R.
    [J]. EMBO JOURNAL, 2016, 35 (20) : 2263 - 2263
  • [3] Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases
    Bell, IM
    Stirdivant, SM
    Ahern, J
    Culberson, JC
    Darke, PL
    Dinsmore, CJ
    Drakas, RA
    Gallicchio, SN
    Graham, SL
    Heimbrook, DC
    Hall, DL
    Hua, J
    Kett, NR
    Kim, AS
    Kornienko, M
    Kuo, LC
    Munshi, SK
    Quigley, AG
    Reid, JC
    Trotter, BW
    Waxman, LH
    Williams, TM
    Zartman, CB
    [J]. BIOCHEMISTRY, 2005, 44 (27) : 9430 - 9440
  • [4] Bradshaw JM, 2015, NAT CHEM BIOL, V11, P525, DOI [10.1038/NCHEMBIO.1817, 10.1038/nchembio.1817]
  • [5] KINETICS OF HYDROLYSIS OF HYDROXY AND METHOXY DERIVATIVES OF N-BENZYLIDENE-2-AMINOPROPANE
    BRUYNEEL, W
    CHARETTE, JJ
    DEHOFFMA.E
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1966, 88 (16) : 3808 - &
  • [6] The structure of C290A:C393A Aurora A provides structural insights into kinase regulation
    Burgess, Selena G.
    Bayliss, Richard
    [J]. ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2015, 71 : 315 - 319
  • [7] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
    Byrd, John C.
    Furman, Richard R.
    Coutre, Steven E.
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie A.
    Grant, Barbara
    Sharman, Jeff P.
    Coleman, Morton
    Wierda, William G.
    Jones, Jeffrey A.
    Zhao, Weiqiang
    Heerema, Nyla A.
    Johnson, Amy J.
    Sukbuntherng, Juthamas
    Chang, Betty Y.
    Clow, Fong
    Hedrick, Eric
    Buggy, Joseph J.
    James, Danelle F.
    O'Brien, Susan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) : 32 - 42
  • [8] The Cysteinome of Protein Kinases as a Target in Drug Development
    Chaikuad, Apirat
    Koch, Pierre
    Laufer, Stefan A.
    Knapp, Stefan
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (16) : 4372 - 4385
  • [9] The drug-target residence time model: a 10-year retrospective
    Copeland, Robert A.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (02) : 87 - 95
  • [10] Ligand Conformational Bias Drives Enantioselective Modification of a Surface-Exposed Lysine on Hsp90
    Cuesta, Adolfo
    Wan, Xiaobo
    Burlingame, Alma L.
    Taunton, Jack
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2020, 142 (07) : 3392 - 3400